SUZETRIGINE IN TCCC 2026

The first NaV1.8 non-opioid analgesic enters modern Tactical Combat Casualty Care doctrine

Operational, pharmacological, doctrinal and battlefield implications in the era of prolonged casualty care and denied evacuation

By DrRamonReyesMD ⚕️
EMS Solutions International
Updated 2026

---

INTRODUCTION

The incorporation of into the 2026 guidelines is not merely the addition of another pain medication.

It represents:

A DOCTRINAL SHIFT IN TACTICAL ANALGESIA.

For the first time, modern TCCC officially integrates a:

• selective NaV1.8 inhibitor,
• non-opioid,
• non-NSAID,
• non-ketamine,
• non-gabapentinoid analgesic

inside the official:

COMBAT WOUND MEDICATION PACK (CWMP)

for casualties categorized as:

“MISSION CAPABLE / STAY IN THE FIGHT”.

Official TCCC 01 MAY 2026 guidelines confirm the inclusion.

---

WHY THIS MATTERS

For two decades, battlefield analgesia largely revolved around:

• opioids,
• ketamine,
• NSAIDs,
• acetaminophen,
• local/regional anesthesia.

But modern warfare changed the operational environment.

Ukraine, FPV drone warfare, prolonged extraction timelines, denied evacuation corridors, and Persistent Casualty Care realities exposed a critical problem:

ANALGESIA THAT IMPAIRS RESPIRATION OR COGNITION CAN KILL.

TCCC 2026 increasingly emphasizes:

• airway preservation,
• respiratory preservation,
• ETCO₂ awareness,
• prolonged field survivability,
• cognitive preservation,
• operational sustainability.

Suzetrigine fits directly into this evolving philosophy.

---

WHAT EXACTLY IS SUZETRIGINE?

Suzetrigine (commercial name in the United States: JOURNAVX) became the:

FIRST FDA-APPROVED SELECTIVE NaV1.8 ANALGESIC

approved January 30, 2025.

Unlike opioids, it does not act primarily on:

• μ-opioid receptors,
• NMDA receptors,
• GABA pathways,
• cyclooxygenase inhibition.

Instead:

it selectively inhibits:

VOLTAGE-GATED SODIUM CHANNEL NaV1.8

predominantly expressed in peripheral nociceptive neurons.

---

PHARMACOLOGICAL SIGNIFICANCE

NaV1.8 channels are heavily involved in:

• nociceptive signal initiation,
• inflammatory pain transmission,
• peripheral pain propagation.

Suzetrigine attempts to interrupt pain transmission:

BEFORE IT REACHES CENTRAL PROCESSING.

That distinction is critical.

Instead of suppressing consciousness or altering CNS perception globally:

it targets peripheral nociceptive conduction itself.

---

THE OPERATIONAL GOAL

The central doctrinal attraction is straightforward:

PROVIDE ANALGESIA WITHOUT RESPIRATORY DEPRESSION.

This is enormously important in:

• prolonged casualty care,
• delayed evacuation,
• austere medicine,
• mountain warfare,
• maritime operations,
• denied airspace,
• arctic operations,
• subterranean warfare,
• special operations sustainment.

---

TCCC 2026 DOSING

According to official CoTCCC guidance:

used alongside:

• acetaminophen,
• meloxicam,

inside the CWMP.

---

THIS IS EXTREMELY IMPORTANT

Suzetrigine is:

NOT positioned as a replacement for ketamine.

Nor as a replacement for severe trauma opioid management.

Instead:

TCCC places it specifically in the:

“MISSION CAPABLE” ANALGESIA LAYER.

Meaning:

• ambulatory casualties,
• moderate pain,
• preserved combat effectiveness,
• prolonged sustainment.

---

WHY THE MILITARY IS INTERESTED

Traditional opioids create major battlefield problems:

Respiratory depression

Especially dangerous during:

• prolonged transport,
• hypoxia,
• chest trauma,
• blast injury,
• sedation layering.

---

Cognitive impairment

Operationally disastrous in:

• ongoing firefights,
• maneuver warfare,
• ISR coordination,
• radio communication,
• navigation.

---

Sedation

Can impair:

• decision-making,
• weapon handling,
• awareness,
• extraction coordination.

---

SUZETRIGINE’S THEORETICAL ADVANTAGE

The promise is:

ANALGESIA WITH PRESERVED MENTATION AND RESPIRATION.

That is operational gold in modern warfare.

---

BUT THERE IS A PROBLEM

The enthusiasm currently exceeds the real-world battlefield evidence.

That distinction matters enormously.

---

CURRENT EVIDENCE BASE

Most robust clinical evidence currently comes from:

POSTOPERATIVE CIVILIAN PAIN TRIALS

not:

• blast injuries,
• polytrauma,
• hemorrhagic shock,
• prolonged field care,
• severe burns,
• crush syndrome,
• cold weather casualties,
• TBI.

---

PHASE 3 DATA

Published phase 3 trials demonstrated superiority versus placebo in:

• abdominoplasty,
• bunionectomy pain models.

DOI: 10.1097/ALN.0000000000005460

But:

SURGICAL PAIN ≠ COMBAT TRAUMA.

---

PHARMACOKINETIC CONCERNS IN PCC

This is where the serious tactical questions begin.

---

ORAL ABSORPTION

Suzetrigine is oral.

That creates immediate PCC concerns:

• gut hypoperfusion,
• shock states,
• delayed gastric emptying,
• vomiting,
• nausea,
• impaired GI absorption.

---

QUESTION:

What happens in:

• hemorrhagic shock,
• hypothermia,
• catecholamine-driven vasoconstriction,
• severe dehydration?

We do not yet possess meaningful battlefield-scale data.

---

TIMING

The article states:

• onset ~30–60 min,
• peak ~2–3 h fasting,
• up to ~5 h fed state.

That may be acceptable in:

• sustained operations,
• moderate injury.

But potentially problematic in:

• dynamic trauma,
• severe battlefield pain,
• extraction under fire.

---

IT IS NOT KETAMINE

This point cannot be overstated.

Suzetrigine does NOT provide:

• dissociation,
• procedural analgesia,
• sedation,
• amnesia,
• rapid severe trauma analgesia.

It cannot currently replace ketamine in:

• amputations,
• blast trauma,
• evisceration,
• severe orthopedic trauma,
• chest trauma,
• prolonged painful procedures.

---

NO AIRWAY CONTROL BENEFIT

Ketamine offers unique tactical value because it:

• preserves airway reflexes relatively well,
• maintains respiratory drive,
• allows procedural management.

Suzetrigine does not replace those capabilities.

---

COGNITIVE EFFECTS

One of the most interesting theoretical advantages:

PRESERVED COMBAT FUNCTION.

If large-scale operational data confirms:

• minimal sedation,
• preserved cognition,
• reduced psychomotor impairment,

this could become revolutionary for:

• SOF,
• reconnaissance,
• maritime interdiction,
• austere patrol medicine,
• denied-area sustainment.

---

ADDICTION POTENTIAL

Because it lacks μ-opioid receptor activity:

theoretical addiction risk appears lower than opioids.

This is strategically relevant given the military’s historical struggle with:

• opioid exposure,
• chronic pain transition,
• dependence risk.

---

SIDE EFFECTS REPORTED

Currently reported adverse effects include:

• nausea,
• dizziness,
• itching,
• muscle spasms.

Compared with hydrocodone/acetaminophen combinations:

trials suggest lower:

• nausea,
• vomiting,
• sedation burden.

---

TACTICAL LIMITATIONS

Not useful if casualty cannot swallow

Not appropriate in:

• unconscious casualties,
• severe facial trauma,
• active vomiting,
• aspiration risk,
• severe TBI with airway compromise.

---

NOT FOR RAPID ANALGESIA

Battlefield pain often requires:

• immediate effect,
• rapid titration,
• procedural flexibility.

Oral pharmacology has inherent delays.

---

LOGISTICS

Suzetrigine is:

• new,
• expensive,
• limited availability,
• not globally distributed.

This matters in:

• coalition operations,
• austere deployments,
• low-resource military systems.

---

THE REAL DOCTRINAL MESSAGE

The most important point is not the drug itself.

The most important point is what CoTCCC is signaling:

MODERN BATTLEFIELD MEDICINE IS MOVING TOWARD RESPIRATORY-SPARING ANALGESIA.

That reflects:

• prolonged evacuations,
• denied extraction,
• drone warfare,
• extended field stabilization,
• reduced “Golden Hour” assumptions.

---

THIS IS A PCC DRUG

Suzetrigine makes far more sense when viewed through:

PROLONGED CASUALTY CARE DOCTRINE

rather than legacy GWOT evacuation assumptions.

---

QUESTIONS STILL UNANSWERED

Major unresolved operational questions include:

• efficacy during hemorrhagic shock,
• absorption under vasoconstriction,
• interaction with ketamine,
• use in TBI,
• performance in hypothermia,
• blast injury efficacy,
• prolonged operational cognition,
• interaction with whole blood resuscitation,
• field pharmacokinetics,
• effectiveness in severe nociceptive overload.

---

OPERATIONAL REALITY

At present:

Suzetrigine appears most promising for:

• ambulatory casualties,
• moderate pain,
• prolonged sustainment,
• opioid-sparing strategies,
• respiratory-risk environments.

But:

IT IS NOT A MIRACLE DRUG.

And it is definitely not replacing:

• ketamine,
• advanced analgesia,
• procedural sedation,
• multimodal severe trauma management.

---

CONCLUSION

Suzetrigine’s inclusion in TCCC 2026 is historically important because it marks:

THE FIRST MAJOR MODERN NON-OPIOID PERIPHERAL ANALGESIC SHIFT IN TACTICAL DOCTRINE.

The military interest is logical:

• preserve breathing,
• preserve cognition,
• reduce opioid burden,
• sustain operational capability.

However:

battlefield medicine has repeatedly shown that:

PHARMACOLOGY THAT LOOKS EXCELLENT IN CONTROLLED TRIALS MAY BEHAVE VERY DIFFERENTLY IN REAL COMBAT TRAUMA.

Suzetrigine deserves serious attention.

But it also deserves:

• skepticism,
• operational auditing,
• battlefield data,
• and rigorous PCC evaluation before doctrinal overconfidence.

---

REFERENCES

Next Generation Combat Medic

---

Official TCCC Guidelines 01 MAY 2026

---

FDA Prescribing Information

---

Pharmacology Review

DOI: 10.1007/s40122-024-00697-0

---

Phase 3 Clinical Trials

DOI: 10.1097/ALN.0000000000005460

---

FDA Approval Commentary

DOI: 10.1213/ANE.0000000000007550

---

Nonopioid Analgesia Review

DOI: 10.1002/hsr2.70132

Suzetrigine is already being given by military providers stateside, and it has been added to the TCCC guidelines. But not many are familiar yet.

We wrote a guide so medics, their instructors and providers can be more familiar with this new option.

https://nextgencombatmedic.com/2026/05/27/suzetrigine/

What questions do you have?

If you’re already giving this, please chime in, let us know how it works for you, side effects you’ve seen, and send corrections on article.